Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00937495 · ClinicalTrials.gov registry record · Phase 2

Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma

A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
16
Enrollment target
6
Study locations

NCT00937495 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants, below the 87-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00937495, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target
6
Study locations

Study Summary

This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.

Conditions Studied

Recurrent Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma

Interventions

  • DRUG vorinostat
  • DRUG bortezomib

Study Locations (6)

Minnesota

  • Mayo Clinic - Rochester
  • Metro-Minnesota CCOP - Saint Louis Park

Florida

  • Mayo Clinic in Florida - Jacksonville

Maryland

  • Johns Hopkins University - Baltimore

Missouri

  • Washington University School of Medicine - St Louis

Wisconsin

  • University of Wisconsin Hospital and Clinics - Madison

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2009-06
Est. Completion 2011-06
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00937495

The ClinicalTrials.gov registry entry for NCT00937495 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (82% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which vorinostat is the first listed.

NCT00937495 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Minnesota, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT00937495 about?

NCT00937495 is a clinical study titled "Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma". This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with borte...

What is the current status of trial NCT00937495?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-06. Estimated completion is 2011-06.

What conditions does trial NCT00937495 study?

This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma.

What interventions are being tested in trial NCT00937495?

The interventions under investigation include: vorinostat (DRUG), bortezomib (DRUG).

Who is sponsoring clinical trial NCT00937495?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00937495 being conducted?

This trial has 6 study locations across Florida, Maryland, Minnesota, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Adult Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Adult Soft Tissue Sarcoma

All registered trials for this condition

Stage IV Adult Soft Tissue Sarcoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.